Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.
After years of caution and setbacks, several drug companies are preparing to capitalize on what they hope will be a surge in sales from prescription medicines linked to the growing global trend of obesity.
"It has been a very challenged category, but there is a feeling we have to do something about obesity with the realization that it is a medical epidemic," says Peter Tam, president of Vivus, a California-based biotechnology company. Last autumn it launched Qsymia, the first weight loss drug to win US regulatory approval in 13 years.
http://www.cnbc.com/id/100340682
Bet they're rubbing their hands
After years of caution and setbacks, several drug companies are preparing to capitalize on what they hope will be a surge in sales from prescription medicines linked to the growing global trend of obesity.
"It has been a very challenged category, but there is a feeling we have to do something about obesity with the realization that it is a medical epidemic," says Peter Tam, president of Vivus, a California-based biotechnology company. Last autumn it launched Qsymia, the first weight loss drug to win US regulatory approval in 13 years.
http://www.cnbc.com/id/100340682
Bet they're rubbing their hands